Form 4: Beta Bionics CFO Sells Shares After Option Exercise

Beta Bionics' Chief Financial Officer, Stephen Feider, executed a pre-planned sale of 20,000 common shares following the exercise of stock options.

Summary

• Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions involving the company's common stock.
• On January 2, 2026, Feider exercised employee stock options to acquire 20,000 shares of common stock at an exercise price of $5.1 per share.
• Concurrently, on January 2, 2026, Feider sold 20,000 shares of common stock at a weighted average sale price of $29.534002 per share, with prices ranging from $29.09 to $30.06.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025.
• Following these transactions, Feider directly beneficially owns 42,614 shares of common stock and 49,695 employee stock options.
• The options exercised were part of a grant that vests in 48 equal monthly installments starting September 14, 2023, and expire on September 13, 2033.

Sentiment

Score: 6

Explanation: The filing reports an insider transaction where the CFO exercised options and sold shares for a profit. While insider selling can sometimes be viewed negatively, the transaction was pre-planned under a 10b5-1 plan, mitigating immediate negative implications. The profit realized is a positive for the individual.

Positives

• The CFO realized a significant profit from exercising options at $5.1 and selling shares at an average of $29.534, indicating personal financial gain.
• The transaction was executed under a pre-arranged Rule 10b5-1 plan, which suggests a planned liquidity event rather than a reaction to new, undisclosed information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence, although it is a common practice for diversification and liquidity.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe insider selling, which could lead to minor shifts in sentiment, though the 10b5-1 plan context often mitigates strong negative reactions.

Key Dates

Keywords

Beta Bionics, BBNX, Stephen Feider, CFO, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Equity Compensation